Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01173679 · ClinicalTrials.gov registry record · Phase 2
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01173679: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01173679 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01173679, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are similar diseases of the white blood cells and are typically treated the same way. Recent research shows that a key enzyme in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory studies show that inhibition of LYN kinase in CLL cells results in the death of CLL cells. Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some effect on CLL cells. The purpose of this study is to see of the study drug dasatinib, in combination with fludarabine and rituximab, is safe and effective to use for people with relapsed or refractory CLL/SLL.
Interventions
- DRUG Rituximab
- DRUG fludarabine
- DRUG dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01173679
The ClinicalTrials.gov registry entry for NCT01173679 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT01173679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01173679 about?
NCT01173679 is a clinical study titled "Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL". Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are similar diseases of the white blood cells and are typically treated the same way. Recent research shows that a key enzyme in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory studies sh...
What is the current status of trial NCT01173679?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01173679?
The interventions under investigation include: Rituximab (DRUG), fludarabine (DRUG), dasatinib (DRUG).
Who is sponsoring clinical trial NCT01173679?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.